Therapeutic potential and strategies for inhibiting tumor necrosis factor-α

Journal of Medicinal Chemistry

Volumn 42, Issue 13, 1999, Pages 2295-2314

  Newton, Robert C ^a   Decicco, Carl P ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3 [5 (2,3 DIMETHOXY 6 METHYL 1,4 BENZOQUINOYL)] 2 NONYL 2 PROPENOIC ACID; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 5 (4 PYRIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; AZELASTINE; BAY 103356; CILOMILAST; CYCLIC AMP; CYCLIC AMP PHOSPHODIESTERASE; DENBUFYLLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MDL 201449A; METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NEUTRALIZING ANTIBODY; NITRAQUAZONE; PHOSPHODIESTERASE INHIBITOR; PICLAMILAST; RESINIFERATOXIN; ROLIPRAM; SB 206718; SPHINGOMYELIN PHOSPHODIESTERASE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; THALIDOMIDE DERIVATIVE; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; CACHEXIA; CELL ACTIVATION; CONGESTIVE HEART FAILURE; CROHN DISEASE; DRUG MECHANISM; ENZYME INHIBITION; ERYTHEMA NODOSUM LEPROSUM; HUMAN; INFLAMMATORY DISEASE; MONOCYTE; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE;

ANIMALS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CYCLIC AMP; DRUG DESIGN; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; METALLOENDOPEPTIDASES; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033168031     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980541n     Document Type: Review

References (249)

1. Carswell, E. A.; Old, L. J.; Kassel, R. L.; Green, S.; Fiore, N.; Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U.S.A. 1975, 72, 3666-3670.
2. Old, L. Tumor necrosis factor (TNF). Science 1985, 230, 630-632.
3. Pennica, D.; Nedwin, G.; Hayflick, J.; Seeburg, P.; Derynck, R.; Palladino, M.; Kohr, W.; Aggarwal, B.; Goeddel, D. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984, 312, 724-729.
4. Elliott, M.; Maini, R.; Feldmann, M.; Kalden, J.; Antoni, C.; Smolen, J.; Leeb, B.; Breedveld, F.; Macfarlane, J.; Bijl, H.; Woody, J. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344, 1105-1110.
5. Gearing, A. J. H.; Beckett, P.; Christodoulou, M.; Churchill, M.; Clements, J.; Davidson, A. H.; Drummond, A. H.; Galloway, W, A.; Gilbert, R.; Gordon, J. L.; Leber, T. M.; Mangan, M.; Miller, K.; Nayee, P.; Owen, K.; Patel, S.; Thomas, W.; Wells, G.; Wood, L. M.; Woolley, K. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994, 370, 555-557.
6. Black, R; Rauch, C.; Kozlosky, C.; Peschon, J.; Slack, J.; Wolfson, M.; Castner, B.; Stocking, K.; Reddy, P.; Srinivasan, S.; Nelson, N.; Bolani, N.; Schooley, K.; Gerhart, M.; Davis, R.; Fitzner, J.; Johnson, R.; Paxton, R.; March, C.; Cerretti, D. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 1997, 385, 729-733.
7. Moss, M.; Jin, S.; Milla, M.; Burkhart, W.; Carter, H.; Chen, W.; Clay, W.; Didsbury, J.; Hassler, D.; Hoffman, C.; Kost, T.; Lambert, M.; Leesnitzer, M.; McCauley, P.; McGeehan, G.; Mitchell, J.; Moyer, M.; Pahel, G.; Rocque, W.; Overton, L.; Schoenen, F.; Seaton, T.; Su, J.; Warner, J.; Willard, D.; Becherer, J. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997, 385, 733-736.
8. Hotamisligil, G.; Arner, P.; Caro, J.; Atkinson, R.; Spiegelman, B. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 1995, 95, 2409-2415.
9. Selmaj, K.; Raine, C.; Cannella, B.; Brosnan, C. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 1991, 87, 949-954.
10. Landow, L.; Andersen, L. Splanchnic ischaemia and its role in multiple organ failure. Acta Anaesthesiol. Scand. 1994, 38, 626-639.
11. Miyazaki, Y.; Araki, K.; Vesin, C.; Garcia, I.; Kapanci, Y.; Whitsett, J.; Piguet, P.; Vassalli, P. Expression of a tumor necrosis factor-α transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J. Clin. Invest. 1995, 96, 250-259.
12. Rus, H.; Niculescu, F.; Vlaicu, R. Tumor necrosis factor-alpha in human arterial wall with atherosclerosis. Atherosclerosis 1991, 89, 247-254.
13. Pfeffer, K.; Matsuyama, T.; Kundig, T.; Wakeham, A.; Kishihara, K.; Shahinian, A.; Wiegmann, K.; Ohaski, P.; Kronke, M.; Mak, T. Mice deficient for the 55 kD tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993, 73, 457-467.
14. Rothe, J.; Lesslauer, W.; Lotscher, H.; Lang, Y.; Koebel, P.; Kontgen, F.; Althage, A.; Zinkernagel, R.; Steinmetz, M.; Bluethmann, H. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993, 364, 798-802.
15. Mon, L.; Iselin, S.; De Libero, G.; Lesslauer, W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J. Immunol. 1996, 157, 3178-3182.
16. Marino, M.; Dunn, A.; Grail, D.; Inglese, M.; Noguchi, Y.; Richards, E.; Jungbluth, A.; Wada, H.; Moore, M.; Williamson, B.; Basu, S.; Old, L. Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 8093-8098.
17. Georgopoulos, S.; Plows, D.; Kolias, G. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J. Inflamm. 1996, 46, 86-97.
18. Keffer, J.; Probert, L.; Cazlaris, H.; Georgopoulos, S.; Kaslaris, E.; Kioussis, D.; Kollias, G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991, 10, 4025-4031.
19. Yamada, Y.; Kirillova, I.; Peschon, J.; Fausto, N. Initiation of liver growth by tumor necrosis factor: Deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 1441-1446.
20. Steinshamm, S.; Bemelmans, M.; van Tits, L.; Bergh, K.; Buurman, W.; Waage, A. TNF receptors in murine Candida albicans infection: evidence for an important role of TNF receptor p55 in antifungal defense. J. Immunol. 1996, 157, 2155-2159.
21. Vieira, L.; Goldschmidt, M.; Nashleanas, M.; Pfeffer, K.; Mak, T.; Scott, P. Mice lacking the TNF receptor p55 fail to resolve lesions caused by infection with Leishmania major, but control parasite replication. J. Immunol. 1996, 157, 827-835.
22. Matsumoto, M.; Mariathasan, S.; Nahm, M.; Baranyay, F.; Peschon, J.; Chaplin, D. Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers. Science 1996, 271, 1289-1291.
23. Nashleanas, M.; Kanaly, S.; Scott, P. Control of Leishmania major infection in mice lacking TNF receptors. J. Immunol. 1998, 160, 5506-5513.
24. Marriott, J.; Westby, M.; Dalgleish, A. Therapeutic potential of TNF-α inhibitors old and new. Drug Discovery Today 1997, 2, 273-282.
25. Shire, M.; Muller, G. TNF-α inhibitors and rheumatoid arthritis. Exp. Opin. Ther. Patents 1998, 8, 531-544.
26. Black, R.; Bird, T.; Mohler, K. Agents that block TNF-α synthesis or activity. Annu. Rep. Med. Chem. 1997, 32, 241-250.
27. Aggarwal, B.; Natarajan, K. Tumor necrosis factors: developments during the past decade. Eur. Cytokine. Network 1996, 7, 93-124.
28. Vandenabeele, P.; Declercq, W.; Beyaert, R.; Fiers, W. Two tumour necrosis factor receptors: structure and function. Trends Cell. Biol. 1995, 5, 392-399.
29. Thomas, P.; Pennington, D.; Schreck, R.; Levine, T.; Lazarus, S. Authentic 17kDa tumour necrosis factor α is synthesized and released by canine mast cells and up-regulated by stem cell factor. Clin. Exp. Allergy 1996, 26, 710-718.
30. Hide, I.; Toriu, N.; Nuibe, T.; Inoue, A.; Hide, M.; Yamamoto, S.; Nakata, Y. Suppression of TNF-α secretion by azelastine in a rat mast cell (RBL-2H3) cell iine: evidence for differential regulation of TNF-α release, transcription, and degranulation. J. Immunol. 1997, 159, 2932-2940.
31. Michie, H.; Manogue, K.; Spriggs, D.; Revhaug, A.; O'Dwyer, S.; Dinarello, C.; Cerami, A.; Wolff, S.; Wilmore, D. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 1988, 318, 1481-1486.
32. Fenton, M.; Golenbock, D. LPS-binding proteins and receptors. J. Leukocyte Biol. 1998, 64, 25-32.
33. Wright, S. Multiple receptors for endotoxin. Curr. Opin. Immunol. 1991, 3, 83-90.
34. Kirkland, T.; Finley, F.; Leturcq, D.; Moriarty, A.; Lee, J.; Ulevitch, R.; Tobias, P. Analysis of lipopolysaccharide binding by CD14. J. Biol. Chem. 1993, 268, 24818-24823.
35. Lynn, W.; Golenbock, D. Lipopolysaccharide antagonists. Immunol. Today 1992, 13, 271-276.
36. di Giovine, F.; Malawista, S.; Thornton, E.; Duff, G. Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. J. Clin. Invest. 1991, 87, 1375-1381.
37. Beezhold, D.; Personius, C. Fibronectin fragments stimulate tumor necrosis factor secretion by human monocytes. J. Leukocyte Biol. 1992, 51, 59-64.
38. Peat, E.; Augustine, N.; Drummond, W.; Bohnsack, J.; Hill, H. Effects of fibronectin and group B streptococci on tumour necrosis factor-α production by human culture-derived macrophages. Immunology 1995, 84, 440-445.
39. 2+, NF-κB binding, and transcription of the TNF-α gene in murine macrophages. J. Leukocyte Biol. 1996, 60, 784-792.
40. Jovanovic, D.; Di Battista, J.; Martel-Pelletier, J.; Jolicoeur, F.; He, Y.; Zhang, M.; Mineau, F.; Pelletier, J. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNF-α, by human macrophages. J. Immunol. 1998, 160, 3513-3521.
41. Stancovski, I.; Baltimore, D. NF-κB activation: the IκB kinase revealed? Cell 1997, 91, 299-302.
42. Baeuerle, P.; Baltimore, D. NF-κB: Ten years after. Cell 1996, 87, 13-20.
43. Weih, F.; Carrasco, D.; SK, D.; Barton, D.; Rizzo, C.; Ryseck, R.; Lira, S.; Bravo, R. Multiorgan inflammation and hematopoietic abnormalities in mice with targeted disruption of RelB, a member of the NF-κB/Rel family. Cell 1995, 80, 331-340.
44. Koentgen, F.; Grumont, R.; Strasser, A.; Metcalf, D.; Li, R.; Tarlinton, D.; Gerondakis, S. Mice lacking the c-rel protooncogene exhibit defects in lymphocyte proliferation, humoral immunity and interleukin-2 expression. Genes Dev. 1995, 9, 1965-1977.
45. Trepicchio, W.; Wang, L.; Bozza, M.; Dorner, A. IL-11 regulates macrophage effector function through the inhibition of nuclear factor-κB. J. Immunol. 1997, 159, 5661-5670.
46. Auphan, N.; DiDonato, J.; Rosette, C.; Helmberg, A.; Karin, M. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis. Science 1995, 270, 286-290.
47. Regnier, C.; Song, H.; Gao, X.; Goeddel, D.; Cao, Z.; Rothe, M. Identification and characterizationof an IκB kinase. Cell 1997, 90, 373-383.
48. Mercurio, F.; Zhu, H.; Murray, B.; Shevchenko, A.; Bennett, B.; Li, J.; Young, D.; Barbosa, M.; Mann, M.; Manning, A.; Rao, A. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science 1997, 278, 860-866.
49. Woronicz, J.; Gao, X.; Cao, Z.; Rothe, M.; Goeddel, D. IκB kinase-B: NF-κB activation and complex formation with IκB kinase-α and NIK. Science 1997, 278, 866-869.
50. Verma, I.; Stevenson, J.; Schwarz, E.; Van Antwerp, D.; Miyamoto, S. Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Dev. 1995, 9, 2723-2735.
51. Malinin, N.; Boldin, M.; Kovalenko, A.; Wallach, D. MAP3K-related kinase invovled in NF-κB induction by TNF, CD95 and IL-1. Nature 1997, 385, 540-544.
52. Mahon, T.; O'Neill, L. Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-κB activation in T lymphocytes: evidence for covalent modification of the p50 subunit. J. Biol Chem. 1995, 270, 28557-28563.
53. Singh, S.; Natarajan, K.; Aggarwal, B. Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a potent inhibitor of nuclear transcription factor-κB activation by diverse agents. J. Immunol. 1996, 157, 4412-4420.
54. Finco, T.; Beg, A.; Baldwin, A. Inducible phosphorylation of IκBα is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 11884-11888.
55. Read, M.; Neish, A.; Gerritsen, M.; Collins, T. Postinduction transcriptional repression of E-selectin and vascular cell adhesion molecule-1. J. Immunol. 1996, 157, 3472-3479.
56. Yaron, A.; Hatzubai, A.; Davis, M.; Lavon, I.; Amit, S.; Manning, A.; Andersen, J.; Mann, M.; Mercurio, F.; Ben-Neriah, Y. Identification of the receptor component of the IκBα-ubiquitin ligase. Nature 1998, 396, 590-594.
57. Jacobs, M.; Harrison, S. Structure of an IκBα/NF-κB complex. Cell 1998, 95, 749-758.
58. Huxford, T.; Huang, D.; Malek, S.; Ghosh, G. The crystal structure of the IκBα/NF-κB complex reveals mechanisms of NF-IκB inactivat ion. Cell 1998, 95, 759-770.
59. Foxwell, B.; Browne, K.; Bondeson, J.; Clarke, C.; de Martin, R.; Brennan, F.; Feldmann, M. Efficient adenoviral infection with IκBα reveals that macrophage tumor necrosis factor α production in rheumatoid arthritis is NF-κB dependent. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 8211-8215.
60. Szallasi, A. The vanilloid (capsaicin) receptor: receptor types and species differences. Gen. Pharmacol. 1994, 25, 223-225.
61. Sun, I.; Sun, E.; Crane, F.; Morre, D.; Lindgren, A.; Low, H. Requirement for coenzyme Q in plasma membrane electron trasnport. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 11126-11130.
62. Suzuki, Y.; Mizuno, M.; Packer, L. Signal transduction for nuclear factor-κB activation: proposed location of antioxidant-inhibitable step. J. Immunol. 1994, 153, 5008-5013.
63. Lahdenpohja, N.; Savinainen, K.; Hurme, M. Preexposure to oxidative stress decreases the nuclear factor-κB-dependent transcription in T lymphocytes. J. Immunol. 1998, 160, 1354-1358.
64. Lange, R.; Germolec, D.; Foley, J.; Luster, M. Antioxidants attenuate anthralin-induced skin inflammation in BALB/c mice: role of specific proinflammatory cytokines. J. Leukocyte Biol. 1998, 64, 170-176.
65. Lange, R.; Hayden, P.; Chignell, C.; Luster, M. Anthralin stimulates keratinocyte-derived proinflammatory cytokines via generation of reactive oxygen species. Inflamm. Res. 1998, 47, 174-181.
66. Onai, N.; Tsunokawa, Y.; Suda, M.; Watanabe, N.; Nakamura, K.; Sugimoto, Y.; Kobayashi, Y. Inhibitory effects of bisbenzyl-isoquinoline alkaloids on induction of proinflammatory cytokines, interleukin-1 and tumor necrosis factor-α. Planta Med. 1995, 61, 497-501.
67. Mattsson, E.; Van Dijk, H.; Van Kessel, K.; Verhoef, J.; Fleer, A.; Rollof, J. Intracellular pathways involved in tumor necrosis factor-α release by human monocytes on stimulation with lipopolysaccharide or staphlococcal peptidoglycan are partly similar. J. Infect. Dis. 1996, 173, 212-218.
68. Brennan, P.; O'Neill, L. Inhibition of nuclear factor kappa-B by direct modification in whole cells - mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers. Biochem. Pharmacol. 1998, 55, 965-973.
69. Sekut, L.; Champion, B.; Page, K.; Menius, J., Jr.; Connolly, K. Antiinflammatory activity of salmetrol: down-regulation of cytokine production. Clin. Exp. Immunol. 1995, 99, 461-466.
70. Chen, Y.; Le Vraux, V.; Giroud, J.; Chauvelot-Moachon, L. Antitumor necrosis factor properties of non-peptide drugs in acute-phase responses. Eur. J. Pharmacol. 1994, 271, 319-327.
71. Alicea, C.; Belkowski, S.; Eisenstein, T.; Adler, M.; Rogers, T. Inhibition of primary murine macrophage cytokine production in vitro following treatment with the κ-opioid agonist U50,488H. J. Neuroimmunol. 1996, 64, 83-90.
72. Seamon, K; Daly, J. Forskolin, cyclic AMP and cellular physiology. Trends Pharmacol. Sci. 1983, 4, 120-123.
73. Kammer, G. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today 1988, 9, 222-229.
74. Haraguchi, S.; Good, R.; Day, N. Immunosuppressive retroviral peptides: cAMP and cytokine patterns. Immunol. Today 1995, 16, 595-603.
75. Jorres, A.; Dinter, H.; Topley, N.; Gahl, G.; Frei, U.; Scholz, P. Inhibition of tumour necrosis factor production in endotoxin-stimulated human mononuclear leukocytes by the prostacyclin analogue iloprost: cellular mechanisms. Cytokine 1997, 9, 119-125.
76. Hai, T.; Curran, T. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 3720-3724.
77. Reinstein, J.; Lichtman, S.; Currin, R.; Wang, J.; Thurman, R.; Lemasters, J. Suppression of lipopolysaccharide-stimulated release of tumor necrosis factor by adenosine: evidence for A2 receptors on rat Kupffer cells. Hepatology 1994, 19, 1445-1449.
78. Bouma, M.; Stad, R.; van den Wildenberg, A.; Buurman, W. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J. Immunol. 1994, 153, 4159-4168.
79. McWhinney, C.; De, M.; Dudley, M.; Bowlin, T.; Peet, N.; Schook, L.; Bradshaw, M.; De, D.; Borcherding, D.; Edwards, C. Activation of adenosine A3 receptors on J774.1 murine macrophages inhibits transcription of LPS-induced tumor necrosis factor-a by blocking NF-κB nuclear translocation. Eur. J. Pharmacol. 1996, 310, 209-216.
80. Sajjadi, F.; Takabayashi, K.; Foster, A.; Domingo, R.; Firestein, G. Inhibition of TNF-α expression by adenosine. Role of A3 adenosine receptors. J. Immunol. 1996, 156, 3435-3442.
81. Hasko, G.; Szabo, C.; Nemeth, Z.; Kvetan, V.; Pastores, S.; Vizi, E. Adenosine receptor agonists differentially regulate IL-10, TNF-a, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol. 1996, 157, 4634-4640.
82. Bradshaw, M.; Rutherford, M.; Schook, L.; Borcherding, D.; McWhinney, C.; Hoeper, B.; Edwards, C. Specfic transcriptional inhibition of bone marrow derived macrophage TNF gene expression and protein production using novel enantomeric carbocyclic nucleoside analogues. J. Pharmacol Exp. Ther. 1995, 273, 1506-1518.
83. Parmely, M.; Zhou, W.; Edwards, C.; Borcherding, D.; Silverstein, R.; Morrison, D. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-α production and protect mice against endotoxin challenge. J. Immunol. 1993, 151, 389-396.
84. LeVraux, V.; Chen, Y.; Masson, I.; DeSousa, M.; Giroud, J.; Florentin, I.; Chauvelot-Moachon, L. Inhibition of human monocyte TNF production by adenosine receptor agonists. Life Sci. 1993, 52, 1917-1924.
85. Munro, S.; Thomas, K.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365, 61-65.
86. Schwarz, H.; Blanco, F.; Lotz, M. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J. Neuroimmunol. 1994, 55, 107-115.
87. Felder, C.; Joyce, K.; Briley, E.; Mansouri, J.; Mackie, K.; Blond, O.; Lai, Y.; Ma, A.; Mitchell, R. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 1995, 48, 443-450.
88. Shirakawa, F.; Mizel, S. In vitro activation and nuclear translocation of NF-κB catalyzed by cyclic AMP-dependent protein kinase and protein kinase C. Mol. Cell. Biol. 1989, 9, 2424-2430.
89. Jeon, Y.; Yang, K.; Pulaski, J.; Kaminski, N. Attenuation of inducible nitric oxide synthase gene expression by tetrahydrocannabinol is mediated through the inhibition of nuclear factor-κB/Rel activation. Mol. Pharmacol. 1996, 50, 334-341.
90. Huffman, J.; Yu, S.; Showalter, V.; Abood, M.; Wiley, J.; Compton, D.; Martin, B.; Bramblett, R.; Reggio, P. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J. Med. Chem. 1996, 39, 3875-3877.
91. Rinaldicarmona, M.; Barth, F.; Millan, J.; Derocq, J.; Casellas, P.; Congy, C.; Oustric, D.; Sarran, M.; Bouaboula, M.; Calandra, B.; Portier, M.; Shire, D.; Breliere, J.; Lefur, G. SR-144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 1998, 284, 644-650.
92. Cavalla, D.; Frith, R. Phosphodiesterase IV inhibitors: Structural diversity and therapeutic potential in asthma. Curr. Med. Chem. 1995, 2, 561-572.
93. Beavo, J.; Conti, M.; Heaslip, R. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 1994, 46, 399-405.
94. Beavo, J. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol. Rev. 1996, 75, 725-748.
95. Thompson, W. Cyclic nucleotide phosphodiesterases pharmacology biochemistry and function. Pharmacol. Ther. 1991, 51, 13-34.
96. Christensen, S.; Torphy, T. Isozyme-selective phosphodiesterase inhibitors as antiasthmatic agents. Annu. Rep. Med. Chem. 1994, 185-194.
97. Christensen, S.; Guider, A.; Forster, C.; Gleason, J.; Bender, P.; Karpinski, J.; Dewolf, W., Jr.; Barnette, M.; Underwood, D.; Griswold, D.; Cieslinski, L.; Burman, M.; Bochnowicz, S.; Osborn, R.; Manning, C.; Grous, M.; Hillegas, L.; Bartus, J.; Ryan, M.; Eggleston, D.; Haltiwanger, R.; Torphy, T. 1,4-Cyclohexanecarboxylates: Potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J. Med. Chem. 1998, 41, 821-835.
98. Kleinman, E.; Campbell, E.; Giordano, L.; Cohan, V.; Jenkinson, T.; Cheng, J.; Shirley, J.; Pettipher, E.; Salter, E.; Hibbs, T.; Dicapua, F.; Bordner, J. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF-alpha inhibitory activity of two series of rolipram analogues: Implications for a new active site model of PDE4. J. Med. Chem. 1998, 41, 266-270.
99. Duplantier, A. J.; Andresen, C. J.; Cheng, J. B.; Cohan, V. L.; Decker, C.; DiCapua, F. M.; Kraus, K. G.; Johnson, K. L.; Turner, C. R.; UmLand, J. P.; Watson, J. W.; Wester, R. T.; Williams, A. S.; Williams, J. A. 7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]-pyridines as novel inhibitors of human eosinophil phosphodiesterase. J. Med. Chem. 1998, 41, 2268-2277.
100. Robinson, M.; Cobb, M. Mitogen-activated protein kinase pathways. Curr. Opin. Cell. Biol. 1997, 9, 180-186.
101. Durando, M.; Meier, K.; Cook, J. Endotoxin activation of mitogen-activated protein kinase in THP-1 cells; diminished activation following endotoxin desensitization. J. Leukocyte Biol. 1997, 64, 259-264.
102. Dumont, F.; Staruch, M.; Fischer, P.; DaSilva, C.; Camacho, R. Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. J. Immunol. 1998, 160, 2579-2589.
103. Rose, D.; Winston, B.; Chan, E.; Riches, D.; Gerwins, P.; Johnson, G.; Henson, P. FCγ receptor cross-linking activates p42, p38, and JNK/SAPK mitogen-activated protein kinases in murine macrophages: role for p42 MAPK in FCγ receptor-stimulated TNF-α synthesis. J. Immunol. 1997, 158, 3433-3438.
104. Zhang, C.; Baumgartner, R.; Yamada, K.; Beaven, M. Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis-factor-α and release of arachionic acid in mast cells: indication of communication between p38 and p42 MAP kinases. J. Biol. Chem. 1997, 272, 13397-13402.
105. Hirano, M.; Osada, S,; Aoki, T.; Hirai, S.; Hosaka, M.; Inoue, J.; Ohno, S. MEK kinase is involved in tumor necrosis factor α-induced NF-κB activation and degradation of IκB-α. J. Biol. Chem. 1996, 271, 13234-13238.
106. Palmer, L.; Hobbie, S.; Galan, J.; Bliska, J. YopJ of Yersinia pseudotuberculosis is required for the inhibition of macrophage TNF-alpha production and downregulation of the MAP kinases p38 and JNK. Mol. Microbiol. 1998, 27, 953-965.
107. Sharpe, T.; Cherkofsky, S.; Hewes, W.; Smith, D.; Gregory, W.; Haber, S.; Leadbetter, M.; Whitney, J. Preparation and antiarthritic and analgesic activity of 4 5 diaryl-2-substituted thio-1h-imidazoles and their sulfoxides and sulfones. J. Med. Chem. 1985, 28, 1188-1194.
108. Young, P.; McDonnell, P.; Dunnington, D.; Hand, A.; Laydon, J.; Lee, J. Pyridinyl imidazoles inhibit IL-1 and TNF production at the protein level. Agents Actions 1993, 39, C67-C69.
109. Prichett, W.; Hand, A.; Sheilds, J.; Dunnington, D. Mechanism of action of bicyclic imidazoles defines a translational regulatory pathway for tumor necrosis factor alpha. J. Inflamm. 1995, 45, 97-105.
110. Gallagher, T. F.; Fier-Thompson, S. M.; Garigipati, R. S.; Sorenson, M. E.; Smietana, J. M.; Lee, D.; Bender, P. E.; Lee, J. C.; Laydon, J. T.; Griswold, D. E.; Chabot-Fletcher, M. C.; Breton, J. J. 2,4,5-Triarylimidazole inhibitors of IL-1 biosynthesis. Bioorg. Med. Chem. Lett. 1995, 5, 1171-1176.
111. Lee, J.; Laydon, J.; McDonnell, P.; Gallagher, T.; Kumar, S.; Green, D.; McNutly, D.; Blumenthal, M.; Heys, J.; Landvatter, S.; Strickler, J.; McLaughlin, M.; Siemens, I.; Fisher, S.; Livi, G.; White, J.; Adams, J.; Young, P. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372, 739-745.
112. Han, J.; Lee, J.; Jiang, Y.; Li, Z.; Feng, L.; Ulevitch, R. Characterization of the structure and function of a novel MAP kinase kinase (MKK6). J. Biol. Chem. 1996, 271, 2886-2891.
113. Lee, J.; Griswold, D.; Votta, B.; Hanna, N. Inhibition of monocyte IL-1 production by the antiinflammatory compound SKF-86002. Int. J. Immunopharmacol. 1988, 10, 835-844.
114. Lin, A.; Minden, A.; Martinetto, H.; Claret, F.; Lange Carter, C.; Mercurio, F.; Johnson, G.; Karin, M. Identification of a dual specificity kinase that activates the jun kinases and p38-Mpk2. Science 1995, 268, 286-290.
115. Beutler, B.; Han, J.; Kruys, V.; Giroir, B. In Tumor Necrosis Factors: The Molecules And Their Emerging Role In Medicine; Beutler, B., Ed.; Raven Press: New York, New York, 1992; pp 561-574.
116. Tong, L.; Pav, S.; White, D.; Rogers, S.; Crane, K.; Cywin, C. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nature Struct. Biol. 1997, 4, 311-316.
117. Wilson, K.; McCaffrey, P.; Hsiao, K.; Pazhanisamy, S.; Galullo, V., Bemis, G.; Fitzgibbon, M.; Caron, P.; Murcko, M.; Su, M. The structural basis for the specific of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. (London) 1997, 4, 423-431.
118. Young, P.; McLaughlin, M.; Kumar, S.; Kassis, S.; Carr, S.; Huddleston, M.; Seibel, G.; Porter, T.; Livi, G.; Adams, J.; Lee, J. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J. Biol. Chem. 1997, 272, 12116-12121.
119. Cuenda, A.; Rouse, J.; Doza, Y. N.; Meier, R.; Cohen, P.; Gallagher, T. F.; Young, P. R.; Lee, J. C. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995, 364, 229-233.
120. Cox, S.; Radzio Andzelm, E.; Taylor, S. Domain movements in protein kinases. Curr. Opin. Struct. Biol. 1994, 4, 893-901.
121. Xu, R.; Carmel, G.; Kuret, J.; Cheng, X. Structural basis for selectivity of the isoquinoline sulfonamide family of protein kinase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 6308-6313.
122. Wilson, K.; Fitzgibbon, M.; Caron, P.; Griffith, J.; Chen, W.; McCaffrey, P.; Chambers, S.; Su, M. Crystal structure of p38 mitogen-activated protein kinase. J. Biol. Chem. 1996, 271, 27696-27700.
123. Griswold, D.; Young, P. Pharmacology of cytokine suppressive antiinflammatory drug binding protein (CSBP), a novel stress-induced kinase. Pharmacol. Commun. 1996, 7, 323-329.
124. Gallagher, T.; Boehn. 215th ACS Meeting 116, Dallas, TX, 1998.
125. Nair, M.; Schwartz, S. Substance P induces tumor necrosis factor in anex vivo model system. Cell. Immunol. 1995, 166, 286-290.
126. Altavilla, D.; Squadrito, F.; Canale, P.; Ioculano, M.; Squadrito, G.; Campo, G.; Serrano, M.; Sardella, A.; Urna, G.; Spignoli, G.; Caputi, A. G619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-α biosynthesis. Eur. J. Pharmacol. 1995, 286, 31-39.
127. Caughey, G.; Pouliot, M.; Cleland, L.; James, M. Regulation of tumor necrosis factor-α and IL-1β synthesis by thromboxane A2 in nonadherent human monocytes. J. Immunol. 1997, 158, 351-358.
128. Siegmund, B.; Eigler, A.; Moeller, J.; Greten, T.; Hartmann, G.; Endres, S. Suppression of tumor necrosis factor-α production by interleukin-10 is enhanced by cAMP-elevating agents. Eur. J. Pharmacol 1997, 321, 231-239.
129. Zurawski, G.; deVries, J. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol. Today 1994,
130. Miller, L.; Hunt, J. Regulation of TNF-α production in activated mouse macrophages by progesterone. J. Immunol. 1998, 160, 5098-5104.
131. De Castro, C.; Nahori, M.; Dumarey, C.; Vargaftig, B.; Bachelet, M. Fenspiride: an antiinflammatory drug with potential benefits in the treatment of endotoxemia. Eur. J. Pharmacol. 1995, 294, 669-676.
132. Cantatore, F.; Introsso, A.; Carrozzo, M. Effects of bisphosphonates on interleukin 1, tumor necrosis factor α, and β2 microglobulin in rheumatoid arthritis. J. Rheumatol. 1996, 23, 1117-1118.
133. Sironi, M.; Milanese, C.; Vecchi, A.; Polenzani, L.; Guglielmotti, A.; Coletta, I.; Landolfi, C.; Soldo, L.; Mantovani, A.; Pinza, M. Benzydamine inhibits the release of tumor necrosis factor-α and monocyte chemotactic protein-1 by Candida albicans-stimulated human peripheral blood cells. Int. J. Clin. Lab. Res. 1997, 27, 118-122.
134. Eigler, A.; Sinha, B.; Hartmann, G.; Endres, S. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol. Today 1997, 10, 487-492.
135. Han, J.; Thompson, P.; Beutler, B. Dexamethasone and pentoxyfylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J. Exp. Med. 1990, 172, 391-394.
136. Sampaio, E.; Sarno, E.; Galilly, R.; Cohn, S.; Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J. Exp. Med. 1991, 173, 699-705.
137. McHugh, S.; Rowland, T. Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-α) inhibition suggest drugs capable of selective gene regulation. Clin. Exp. Immunol. 1997, 110, 151-154.
138. Spies, T.; Morton, C.; Nedospasov, S.; Fiers, W.; Pious, D.; Strominger, J. Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex. Proc. Natl Acad. Sci. U.S.A. 1986, 83, 8699-8702.
139. Campbell, R.; Trowsdale, J. Map of the human MHC. Immunol. Today 1993, 14, 349-352.
140. Mulcahy, B.; Waldron-Lynch, F.; McDermott, M.; Adams, C.; Amos, C.; Zhu, D.; Ward, R.; Clegg, D.; Shanahan, F.; Molloy, M.; O'Gara, F. Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Am. J. Hum. Genet. 1996, 59, 676-683.
141. Shakhov, A.; Kuprash, D.; Azizov, M.; Jongeneel, C.; Nedospasov, S. Structural analysis of the rabbit TNF locus, containing the genes encoding TNF-β (lymphotoxin) and TNF-α (tumor necrosis factor). Gene 1990, 95, 215-221.
142. Takashiba, S.; Shapira, L.; Amar, S.; Van Dyke, T. Cloning and characterization of human TNF alpha promoter region. Gene 1993, 131, 307-308.
143. Shakhov, A.; Collart, M.; Vassali, P.; Nedospasov, S.; Jongeneel, C. κB-type enhancers are involved in LPS-mediated transcriptional activation of the TNF-α gene in primary macrophages. J. Exp. Med. 1990, 171, 35-48.
144. Zagariya, A.; Mungre, S.; Lovis, R.; Birrer, M.; Ness, S.; Thimmapaya, B.; Pope, R. Tumor-necrosis-factor-alpha gene-regulation - enhancement of C/EBP-beta-induced activation by c-jun. Mol. Cell. Biol. 1998, 18, 2815-2824.
145. Vayssiere, B.; Dupont, S.; Choquart, A.; Petit, F.; Garcia, T.; Marchandeau, C.; Gronemeyer, H.; Resche-Rigon, M. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol. Endocrinol. 1997, 11, 1245-1255.
146. Tsai, E.; Jain, J.; Pesavento, P.; Rao, A.; Goldfield, A. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol. Cell. Biol. 1996, 16, 459-467.
147. Hiramoto, M.; Shimizu, N.; Sugimoto, K.; Tang, J.; Kawakami, Y.; Ito, M.; Aizawa, S.; Tanaka, H.; Makino, I.; Handa, H. Nuclear targeted suppression of NF-κB activity by the novel quinone derivative E3330. J. Immunol 1998, 160, 810-819.
148. Kopp, E.; Ghosh, S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994, 265, 956-959.
149. Grilli, M.; Pizzi, M.; Memo, M.; Spano, P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science 1996, 274, 1383-1385.
150. Jarrous, N.; Osman, F.; Kaempfer, R. 2-aminopurine selectively inhibits splicing of tumor necrosis factor alpha mRNA. Mol. Cell. Biol. 1996, 16, 2814-2822.
151. Taylor, G.; Carballo, E.; Lee, D.; Lai, W.; Thompson, M.; Patel, D.; Schenkman, D.; Gilkeson, G.; Broxmeyer, H.; Haynes, B.; Blackshear, P. A pathogenetic role for TNFα in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 1996, 4, 445-454.
152. Kim, Y.; Rus, H.; Fisher, S.; Pitha, P.; Shin, M. Binding of a protein to an AU-rich domain of tumour necrosis factor α mRNA as a 35 kDa complex and its regulation in primary rat astrocytes. Biochem. J. 1996, 316, 455-460.
153. Shohami, E.; Gallily, R.; Mechoulam, R.; Bass, R.; Ben-Hur, T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant. J. Neuroimmunol. 1997, 72, 169-177.
154. Cohen, P.; Nakshatri, H.; Dennis, J.; Caragine, T.; Bianchi, M.; Cerami, A.; Tracey, K. CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 3967-3971.
155. Wolfsberg, T.; Primakoff, P.; Myles, D.; White, J. ADAM, a novel family of membrane proteins containing a disintegrin and metalloprotease domain: Multipotential functions in cell-cell and cell-matrix interactions, J. Cell. Biol. 1995, 131, 275-278.
156. Birkedal-Hansen, H.; Moore, W.; Bodden, M.; Windsor, L.; Birkedal-Hansen, B.; DeCarlo, A.; Engler, J. Matrix metalloproteases: a review. Crit. Rev. Oral. Biol. Med. 1993, 4, 197-250.
157. Beckett, R.; Whittaker, M. Matrix metalloprotease inhibitors. Exp. Opin. Ther. Patents 1998, 8, 259-282.
158. Mohler, K.; Sleath, P.; Fitzner, J.; Cerretti, D.; Alderson, M.; Kerwar, S.; Torrance, D.; Otten-Evans, C.; Greenstreet, T.; Weerawarna, K.; Kronhelm, S.; Petersen, M.; Gerhart, M.; Kozlosky, C.; March, C.; Black, R. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994, 370, 218-220.
159. McGeehan, G.; Becherer, J.; Bast, R., Jr.; Boyer, C.; Champion, B.; Connolly, K.; Conway, J.; Furdon, P.; Karp, S.; Kidao, S.; McElroy, A.; Nichols, J.; Pryzwansky, K; Schoenen, F.; Sekut, L.; Truesdale, A.; Verghese, M.; Warner, J.; Ways, J. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994, 370, 558-561.
160. Decicco, C.; Jaffee, B.; Copeland, R.; Jones, B.; Dimeo, T.; Gardner, T.; Collins, R.; Czerniak, P.; Nelson, D.; Magolda, R. TNF-C inhibitors in models of inflammation. 6th Int. Tumor Necrosis Factor Congress, Rhodes, Greece 1996, 7, 1148-5493.
161. Maskos, K.; Fernandez-Catalan, C.; Huber, R.; Bourenkov, G.; Bartunik, H.; Ellestad, G.; Reddy, P.; Wolfson, M.; Rauch, C.; Castner, B.; Davis, R.; Clarke, H.; Petersen, M.; Fitzner, J.; Cerretti, D.; March, C.; Paxton, R.; Black, R.; Bode, W. Crystal structure of the catalytic domain of human tumor necrosis factor-α-converting enzyme. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 3408-3412.
162. Rosendahl, M.; Ko, S.; Long, D.; Brewer, M.; Rosenzweig, B.; Hedl, E.; Anderson, L.; Pyle, S.; Moreland, J.; Meyers, M.; Kohno, T.; Lyons, D.; Lichenstein, H. Identification and characterization of a pro-tumor necrosis factor-alpha-processing enzyme from the ADAM family of zinc metalloproteases. J. Biol. Chem. 1997, 272, 24588-24593.
163. Lunn, C.; Fan, X.; Dalie, B.; Miller, K.; Zavodny, P.; Narula, S.; Lundell, D. Purification of ADAM 10 from bovine spleen as a TNF-alpha convertase. FEBS Lett. 1997, 400, 333-335.
164. Black, R. A.; Rauch, C. T.; Kozlosky, C. J.; Peschon, J. J.; Slack, J. L.; Wolfson, M. F.; Castner, B. J.; Stocking, K. L.; Reddy, P.; Srinivasan, S.; Nelson, N.; Boiani, N.; Schooley, K. A.; Gerhart, M.; Davis, R.; Fitzner, J. N.; Johnson, R. S.; Paxton, R. J.; March, C. J.; Cerretti, D. P. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385, 729-733.
165. Wingfield, P.; Pain, R.; Craig, S. Tumour necrosis factor is a compact trimer. FEBS Lett. 1987, 211, 179-184.
166. Banner, D.; D'Arcy, A.; Janes, W.; Gentz, R.; Schoenfeld, H.; Broger, C.; Loetscher, H.; Lesslauer, W. Crystal structure of the soluble human 55kd TNF receptor-human TNF/β complex: implications for TNF receptor activation. Cell 1993, 73, 431-445.
167. Heath, P. Use of anti-TNFa therapies as potential treatments for rheumatoid arthritis. ID Res. Alert 1997, 1, 235-240.
168. Van Dullemen, H.; Van Deventer, S.; Hommes, D.; Bijl, H.; Jansen, J.; Tytgat, G.; Woody, J. Treatment of Crohn's disease with antitumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109, 129-135.
169. Davis, D.; Charles, P.; Potter, A.; Feldmann, M.; Maini, R.; Elliott, M. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumor necrosis factor α blockade. Br. J. Rheumatol. 1997, 36, 950-956.
170. van Oosten, B.; Barkhof, F.; Truyen, L.; Boringa, J.; Bertelsmann, F.; von Blomberg, B.; Woody, J.; Hartung, H.; Polman, C. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal antitumor necrosis factor antibody cA2. Neurology 1996, 47, 1531-1534.
171. Rankin, E. C.; Choy, E. H.; Kassimos, D.; Kingsley, G. H.; Sopwith, A. M.; Isenberg, D. A.; Panayi, G. S. The therapeutic effects of an engineered human anti-tumour necrosis factor antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol. 1995, 34, 334-342.
172. Stack, W.; Mann, S.; Roy, A.; Heath, P.; Sopwith, M.; Freeman, J.; Holmes, G.; Long, R.; Forbes, A.; Kamm, M.; Hawkey, C. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997, 349, 521-524.
173. Evans, R.; Clarke, L.; Heath, P.; Stephens, S.; Morris, A.; Rhodes, J. Treatment of ulcerative colitis with an engineered human anti-TNFα antibody CDP571. Aliment Pharmacol. Ther. 1997, 11, 1031-1035.
174. Reinhart, K.; Wiegand-Lohnert, C.; Grimminger, F.; Kaul, M.; Withington, S.; Treacher, D.; Eckart, J.; Willatts, S.; Bouza, C.; Krausch, D.; Stockenhuber, F.; Eiselstein, J.; Daum, L.; Kempeni, J. Assessment of the safety and efficacy of the monoclonal antitumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shcok: A multicenter, randomized, placebo-controlled, dose-ranging study. Crit. Care Med. 1996, 24, 733-742.
175. Seckinger, P.; Zhang, J.; Hauptmann, B.; Dayer, J. Characterization of a tumor necrosis factor α (TNF-α) inhibitor: Evidence of immunological cross-reactivity with the TNF receptor. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 5188-5192.
176. Engelmann, H.; Novick, D.; Wallach, D. Two tumor necrosis factor-binding proteins purified from human urine: Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J. Biol. Chem. 1990, 265, 1531-1536.
177. Nophar, Y.; Kemper, O.; Brakebusch, C.; Engelmann, H.; Zwang, R.; Aderka, D.; Holtmann, H.; Wallach, D. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J. 1990, 9, 3269-3278.
178. Evans, T.; Moyes, D.; Carpenter, A.; Martin, R.; Loetscher, H.; Lesslauer, W.; Cohen, J. Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J. Exp. Med. 1994, 180, 2173-2179.
179. Nicod, L.; Isler, P.; Chicheportiche, R.; Songeon, F.; Dayer, J. Production of prostaglandin EZ and collagenase is inhibited by the recombinant soluble tumour necrosis factor receptor p55-human γ3 fusion protein at concentrations a 100-fold lower than those decreasing T cell activation. Eur. Cytokine Network 1996, 7, 757-763.
180. Abraham, E.; Coulson, W.; Schwartz, M.; Allbee, J. Effects of therapy with soluble tumour necrosis factor receptor fusion protein on pulmonary cytokine expression and lung injury following haemorrhage and resuscitation. Clin. Exp. Immunol. 1994, 98, 29-34.
181. Moreland, L.; Baumgartner, S.; Schiff, M.; Tindall, E.; Fleischmann, R.; Weaver, A.; Ettlinger, R.; Cohen, S.; Koopman, W.; Mohler, K.; Widmer, M.; Blosch, C. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 1997, 337, 141-147.
182. Brouckaert, P.; Ameloot, P.; Cauwels, A.; Everaerdt, B.; Libert, C.; Takahashi, N.; Van Molle, W.; Fiers, W. Receptor-selective mutants of tumour necrosis factor in the therapy of cancer: Preclinical studies. Circ. Shock 1994, 43, 185-190.
183. Upton, C.; Macen, J.; Schreiber, M.; McFadden, G. Myxoma virus expresses a screted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence. Virology 1991, 184, 370-382.
184. Mackay, F.; Rothe, J.; Bluethmann, H.; Loetscher, H.; Lesslauer, W. Differential responses of fibroblasts from wild-type and TNF-R55-deficient mice to mouse and human TNF-α activation. J. Immunol. 1994, 153, 5274-5284.
185. Tartaglia, L.;Pennica, D.; Goeddel, D. Ligand passing: The 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J. Biol. Chem. 1993, 268, 18542-18548.
186. Bazzoni, F.; Beutler, B. How do tumor necrosis factor receptors work? J. Inflamm. 1995, 45, 221-238.
187. Vandevoorde, V.; Haegeman, G.; Fiers, W. Induced expression of trimerized intracellular domains of the human tumor necrosis factor (TNF) p55 receptor elicits TNF effects. J. Cell. Biol. 1997, 137, 1627-1638.
188. Boldin, M.; Mett, I.; Varfolomeev, E.; Chumakov, I.; Shemer-Avni, Y.; Camonis, J.; Wallach, D. Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J. Biol. Chem. 1995, 270, 387-391.
189. Brakebusch, C.; Varfolomeev, E.; Batkin, M.; Wallach, D. Structural requirements for inducible shedding of hte p55 tumor necrosis factor receptor. J. Biol. Chem. 1994, 269, 32488-32496.
190. Crowe, P.; Wlater, B.; Mohler, K.; Otten-Evans, C.; Black, R.; Ware, C. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T-lymphocytes. J. Exp. Med. 1995, 181, 1205-1209.
191. Herman, C.; Chernajovsky, Y. Mutation of proline 211 reduces shedding of the human p75 TNF receptor. J. Immunol. 1998, 160, 2478-2487.
192. Porteu, F.; Hieblot, C. Tumor necrosis factor induces a selective shedding of its p75 receptor from human neutrophils. J. Biol. Chem. 1994, 269, 2834-2840.
193. Yuan, J. Transducing signals of life and death. Curr. Opin. Cell. Biol. 1997, 9, 247-251.
194. Hsu, H.; Xiong, J.; Goeddel, D. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell 1995, 81, 495-504.
195. Chinnaiyan, A.; O'Rourke, K.; Tewari, M.; Dixit, V. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995, 81, 505-512.
196. Chaudhary, P.; Eby, M.; Jasmin, A.; Bookwalter, A.; Murray, J.; Hood, L. Death receptor-5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappa-B pathway. Immunity 1997, 7, 821-830.
197. Chinnaiyan, A.; Tepper, C.; Seldin, M.; O'Rourke, K.; Kischkel, F.; Hellbardt, S.; Krammer, P.; Peter, M.; Dixit, V. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J. Biol. Chem. 1996, 271, 4961-4965.
198. Schneider, P.; Thome, M.; Burns, K.; Bodmer, J.; Hofmann, K.; Kataoka, T.; Holler, N.; Tschopp, J. TRAIL receptor-1 (DR4) and receptor-2 (DR5) signal FADD-dependent apoptosis and activate NF-kappa-B. Immunity 1997, 7, 831-836.
199. Wajant, H.; Johannes, F.; Haas, E., Siemienski, K.; Schwenzer, R.; Schubert, G.; Weiss, T.; Grell, M.; Scheurich, P. Dominant-negative FADD inhibits TNFR60-mediated, FAS/APO1-mediated and TRAIL-R/APO2-mediated cell-death but not gene induction. Curr. Biol. 1997, 8, 113-116.
200. Muzio, M.; Chinnaiyan, A.; Kischkel, F.; O'Rourke, K.; Shevchenko, A.; Ni, J.; Scaffidi, C.; Bretz, J.; Zhang, M.; Gentz, R.; Mann, M.; Krammer, P.; Peter, M.; Dixit, V. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996, 85, 817-827.
201. Boldin, M. P.; Goncharov, T. M.; Goltsev, Y. V.; Wallach, D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996, 85, 803-815.
202. Scaffidi, C.; Medema, J.; Krammer, P.; Peter, M. FLICE is predominatly expressed as 2 functionally active isoforms, caspase-8/a and caspase-8/b. J. Biol. Chem. 1997, 272, 26953-26958.
203. Hsu, H.; Huang, J.; Shu, H.; Baichwal, V.; Goeddel, D. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996, 4, 387-396.
204. McCarthy, J.; Ni, J.; Dixit, V. RIP2 is a novel NK-κB-activating and cell death-inducing kinase. J. Biol Chem. 1998, 273, 16968-16975.
205. Kelliher, M.; Grimm, S.; Ishida, Y.; Kuo, F.; Stanger, B.; Leder, P. The death domain kinase RIP mediates the TNF-induced NF-kappa-B signal. Immunity 1998, 8, 297-303.
206. Hsu, H.; Shum, H.; Pan, M.; Goeddel, D. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996, 84, 299-308.
207. Aoudjit, F.; Brochu, N.; Belanger, B.; Stratowa, C.; Hiscott, J.; Audette, M. Regulation of intercellular adhesion molecule-1 gene by tumor necrosis factor-α is mediated by the nuclear factor-κB heterodimers p65/p65 and p65/cRel in the absence of p50. Cell Growth Differ. 1997, 8, 335-342.
208. Song, H. Y.; Regnier, C. H.; Kirschning, C. J.; Goeddel, D. V.; Rothe, M. Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 9792-9796.
209. Relaix, F.; Wei, X.; Wu, X.; Sassoon, D. PEG3/PW1 is an imprinted gene involved in the TNF-NF-kappa-B signal transduction pathway. Nature Genet. 1998, 18, 287-291.
210. Song, H.; Dunbar, J.; Zhang, Y.; Guo, D.; Donner, D. Identification of a protein with homology to hsp90 that binds the type 1 tumor necrosis factor receptor. J. Biol. Chem. 1995, 270, 3574-3581.
211. Dunbar, J.; Song, H.; Guo, D.; Wu, L.; Donner, D. Two-hybrid cloning of a gene encoding TNF receptor-associated protein 2, a protein that interacts with the intracellular domain of the type 1 TNF receptor. J. Immunol. 1997, 158, 4252-4259.
212. Grell, M.; Zimmermann, G.; Hulser, G.; Pfizenmaier, K.; Scheurich, P. TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways. J. Immunol. 1994, 153, 1963-1968.
213. Ng, P.; Janicke, R.; Porter, A. Mutations which abolish phosphorylation of the TRAF-binding domain of TNF receptor-2 enhance receptor mediated NF-kappa-B activation. Biochem. Biophys. Res. Commun. 1998, 244, 756-762.
214. Rothe, M.; Wong, S.; Henzel, W.; Goeddel, D. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994, 78, 681-692.
215. Weiss, T.; Grell, M.; Hessabi, B.; Bourteele, S.; Muller, G.; Scheurih, P.; Wajant, H. Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80. Requirement of the TNF receptor-associated factor-2 binding site. J. Immunol. 1997, 158, 2398-2404.
216. Uren, A.; Pakusch, M.; Hawkins, C.; Puls, K.; Vaux, D. Cloning and expression of apoptosis inhibitory protein homologues that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proc. Natl. Acad. Sci. U.S.A 1996, 93, 4974-4978.
217. Roy, N.; Deveraux, Q.; Takahashi, R.; Salvesen, G.; Reed, J. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 1997, 16, 6914-6925.
218. Rasper, D.; Vaillancourt, J.; Hadano, S.; Houtzager, V.; Seiden, I.; Keen, S.; Tawa, P.; Xanthoudakis, S.; Nasir, J.; Martindale, D.; Koop, B.; Peterson, E.; Thornberry, N.; Huang, J.; MacPherson, D.; Black, S.; Hornung, F.; Lenardo, M.; Hayden, M.; Roy, S.; Nicholson, D. Cell death attenuation by usurpin, a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (FAS, APO-1) receptor complex. Cell Death Differ. 1998, 5, 271-288.
219. Chen, P.; Tian, J.; Kovesdi, I.; Bruder, J. Interaction of the adenovirus 14.7 kDa protein with FLICE inhibits Fas ligand induced apoptosis. J. Biol. Chem. 1998, 273, 5815-5820.
220. Wang, G.; Bertin, J.; Wang, Y.; Martin, D.; Wang, J. Bovine herpesvirus-4 BORFE2 protein inhibits Fas-induced and tumor necrosis factor receptor-1 induced apoptosis and contains death effector domains shared with other gamma-2 herpesviruses. J. Virol. 1997, 71, 8928-8932.
221. Srinivasan, A.; Li, F.; Wong, A.; Kodandapani, L.; Smidt, R.; Krebs, J.; Fritz, L.; Wu, J.; Tomaselli, K. Bcl-x(L) functions downstream of caspase-8 to inhibit Fas necrosis factor and tumor necrosis factor receptor-1 induced apoptosis of MCF7 breast cancinoma cells. J. Biol. Chem. 1998, 273, 4523-4529.
222. Medema, J.; Scaffidi, C.; Krammer, P.; Peter, M. Bcl-x(L) acts downstream of caspase-8 activation by the CD95 death inducing signaling complex. J. Biol. Chem. 1998, 273, 3388-3393.
223. Brink, R.; Lodish, H. Tumor necrosis factor receptor (TNFR)-associated factor 2A (TRAF2A), a TRAF2 splice variant with an extended ring finger domain that inhibits TNFR2 mediated NF-kappa-B activation. J. Biol. Chem. 1998, 273, 4129-4134.
224. Song, H.; Rothe, M.; Goeddel, D. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-κ-B activation. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 6721-6725.
225. Beg, A.; Baltimore, D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996, 274, 782-784.
226. Wang, C.; Mayo, M.; Baldwin, A., Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996, 274, 784-787.
227. Van Antwerp, D.; Martin, S.; Kafri, T.; Green, D.; Verma, I. Suppression of TNF-α-induced apoptosis by NF-κ-B. Science 1996, 274, 787-789.
228. Liu, Z.; Hsu, H.; Goeddel, D. Dissection of TNF receptor 1 effector function: JNK activation is not linked to apoptosis while NFκB activation prevents cell death. Cell 1996, 87, 565-576.
229. Wu, M.; Ao, Z.; Prasad, K.; Wu, R.; Schlossman, S. IEX-1L, an apoptosis inhibitor involved in NF-κB-mediated cell survival. Science 1998, 281, 998-1001.
230. Ferran, C.; Stroka, D.; Badrichani, A.; Cooper, J.; Wrighton, C.; Soares, M.; Grey, S.; Bach, F. A20 inhibits NFκB activation in endothelial-cells without sensitizing to tumor necrosis factor-mediated apoptosis. Blood 1998, 91, 2249-2258.
231. Schwandner, R.; Wiegmann, K.; Bernardo, K.; Kreder, D.; Kronke, M. TNF receptor death domain-associated proteins TRADD and FADD signal activation of acid sphingomyelinase. J. Biol. Chem. 1998, 273, 5916-5922.
232. Sweeney, E.; Inokuchi, J.; Igarashi, Y. Inhibition of sphingolipid induced apoptosis by caspase inhibitors indicates that sphingosine acts in an earlier part of the apoptotic pathway than ceramide. FEBS Lett. 1998, 425, 61-65.
233. Dbaibo, G.; Perry, D.; Gamard, C.; Platt, R.; Poirier, G.; Obeid, L.; Hannun, Y. Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-α: CrmA and Bcl-2 target distinct components in the apoptotic pathway. J. Exp. Med. 1997, 185, 481-490.
234. Boesendecock, J.; Tepper, A.; DeVries, E.; Van Blitterswijk, W.; Borst, J. CD95 (FAS/APO-1) induces ceramide formation and apoptosis in the absence of a functional acid sphingomyelinase. J. Biol. Chem. 1998, 273, 7560-7565.
235. Monney, L.; Olivier, R.; Otter, I.; Jansen, B.; Poirier, G.; Borner, C. Role of an acidic compartment in tumor necrosis factor alpha induced production of ceramide, activation of caspase-3 and apoptosis. Eur. J. Biochern. 1998, 251, 295-303.
236. Moriguchi, T.; Toyoshima, F.; Masuyama, N.; Hanafusa, H.; Gotoh, Y.; Nishida, E. A novel SAPK/JNK kinase, MKK7, stimulated by TNFα and cellular stresses. EMBO J. 1997, 16, 7045-7053.
237. Natoli, G.; Costanzo, A.; Ianni, A.; Templeton, D.; Woodgett, J.; Balsano, C.; Levrero, M. Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science 1997, 275, 200-203.
238. Marti, A.; Luo, Z.; Cunningham, C.; Ohta, Y.; Hartwig, J.; Stossel, T.; Kyriakis, J.; Avruch, J. Actin-binding protein-280 binds the stress-activated protein kinase (SAPK) activator SEK-1 and is required for tumor necrosis factor-α activation of SAPK in melanoma cells. J. Biol. Chem. 1997, 272, 2620-2628.
239. Lee, F.; Hagler, J.; Chen, Z.; Maniatis, T. Activation of the IκBα kinase complex by MEKK1, a kinase of the JNK pathway. Cell 1997, 88, 213-222.
240. Saltzman, A.; Searfoss, G.; Marcireau, C.; Stone, M.; Ressner, R.; Munro, R.; Franks, C.; D'Alonzo, J.; Tocque, B.; Jaye, M.; Ivashchenko, Y. hUBC9 associates with MEKK1 and type I TNF-α receptor and stimulates NFκB activity. FEBS Lett. 1998, 425, 431-435.
241. Winston, B.; Chan, E.; Johnson, G.; Riches, D. Activation of p38mapk, MKK3, and MKK4 by TNF-α in mouse bone marrow-derived macrophages. J. Immunol. 1997, 159, 4491-4497.
242. Carpentier, I.; Declercq, W.; Malinin, N.; Wallach, D.; Fiers, W.; Beyaert, R. TRAF2 plays a dual role in NFκB-dependent gene activation by mediating the TNF-induced activation of p38 MAPK and IκB kinase pathways. FEBS Lett. 1998, 425, 195-198.
243. Zu, Y.; Qi, J.; Gilchrist, A.; Fernandez, G.; Vazquez-Abad, D.; Kreutzer, D.; Huang, C.; Sha'afi, R. p38 mitogen-activated protein kinase activation is required for human neutrophil function triggered by TNF-α or FMLP stimulation. J. Immunol. 1998, 160, 1982-1989.
244. Vanden Berghe, W.; Plaisance, S.; Boone, E.; De Bosscher, K.; Lienhard Schmitz, M.; Fiers, W.; Haegeman, G. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-κB p65 transactivation mediated by tumor necrosis factor. J. Biol. Chem. 1998, 273, 3285-3290.
245. mapk/erk2 in mouse macrophages. J. Biol. Chem. 1995, 270, 27391-27394.
246. Hotamisligil, G.; Peraldi, P.; Budavari, A.; Ellis, R.; White, M.; Spiegelman, B. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 1996, 271, 665-668.
247. Guo, D.; Dunbar, J.; Yang, C.; Pfeffer, L.; Donner, D. Induction of Jak/STAT signaling by activation of the type 1 TNF receptor. J. Immunol. 1998, 160, 2742-2750.
248. Castellino, A.; Parker, G.; Boronenkov, I.; Anderson, R.; Chao, M. A novel interaction between the juxtamembrane region of the p55 tumor necrosis factor receptor and phosphatidylinositol-4-phosphate 5-kinase. J. Biol. Chem. 1997, 272, 5861-5870.
249. Bergmann, M.; Hart, L.; Lindsay, M.; Barnes, P.; Newton, R. I-kappa-B-alpha degradation and nuclear factor-kappa-B DNA binding are insufficient for interleukin-1 beta and tumor necrosis factor alpha incuded kappa-B-dependent transcription - requirement for an additional activation pathway. J. Biol. Chem. 1998, 273, 6607-6610.